Altimmune (NYSE:ALT) is set to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Altimmune (NYSE:ALT) last announced its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The company had revenue of $1.63 million for the quarter, compared to analyst estimates of $2.41 million.
Shares of ALT opened at $1.78 on Tuesday. The firm’s 50 day simple moving average is $1.96 and its 200 day simple moving average is $2.27. Altimmune has a 1-year low of $1.70 and a 1-year high of $5.94.
Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.